PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV (pharmacovigilance) issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Search narrowed by
Vinorelbine
PSUR-outcome
|
30/01/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Triptorelin
PSUR-outcome
|
30/01/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Amoxicillin / Clavulanate
PSUR-outcome
|
17/01/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Amoxicillin
PSUR-outcome
|
13/01/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Erythromycin (systemic use)
PSUR-outcome
|
12/01/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Fexofenadine
PSUR-outcome
|
09/01/2023
Further information and amendments to the product information in all EU languages are available on the EMA website.
Oxycodone
PSUR-outcome
|
22/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Levothyroxine
PSUR-outcome
|
02/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Mesterolone
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Gabapentin
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
